Hepatitis D Virus

This year’s The Liver Meeting provided many exciting updates for viral hepatitis care ranging from steps toward eliminating hepatitis C to improving hepatitis B treatment options through data on hepatitis D.

BOSTON — Triple combination therapy with lonafarnib, ritonavir, and Lambda for chronic hepatitis D appeared safe and tolerable for up to 6 months in most patients and led to high rates of RNA decline, according to data presented at The Liver Meeting 2019.